Pharmosa Biopharm Inc. (TPEX:6875)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
39.35
-0.25 (-0.63%)
Mar 24, 2026, 1:30 PM CST

Pharmosa Biopharm Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
5,0806,7006,82910,3147,055-
Market Cap Growth
-33.42%-1.89%-33.79%46.18%--
Enterprise Value
4,0485,5875,3389,3306,778-
Last Close Price
39.3551.9052.9088.0062.22-
PE Ratio
---1219.72--
PS Ratio
75.5199.6040.7532.80--
PB Ratio
3.264.303.529.079.27-
P/TBV Ratio
3.264.303.539.079.27-
P/OCF Ratio
---327.98--
EV/Sales Ratio
60.1883.0631.8629.67--
EV/EBITDA Ratio
---3121.44--
Debt / Equity Ratio
0.060.060.060.130.030.07
Debt / EBITDA Ratio
---7.04--
Net Debt / Equity Ratio
-0.66-0.66-0.77-0.73-0.86-0.80
Net Debt / EBITDA Ratio
2.782.787.32-277.582.451.67
Net Debt / FCF Ratio
2.172.175.1316.592.431.76
Asset Turnover
0.030.030.100.30--
Inventory Turnover
2.442.441.74---
Quick Ratio
11.4611.4614.0312.5824.2313.96
Current Ratio
12.1112.1114.4813.0224.6514.39
Return on Equity (ROE)
-21.96%-21.96%-10.84%0.89%-41.24%-54.73%
Return on Assets (ROA)
-12.87%-12.87%-7.81%-0.17%-24.49%-28.67%
Return on Capital Employed (ROCE)
-24.40%-24.40%-10.70%-0.20%-35.20%-46.80%
Earnings Yield
-7.56%-5.73%-2.44%0.08%-3.78%-
FCF Yield
-9.37%-7.11%-4.28%-0.48%-3.81%-
Buyback Yield / Dilution
-2.23%-2.23%-11.49%-15.09%-16.02%-78.34%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.